BioNTech

BioNTech的十字路口：疫苗现金牛与肿瘤野心的双重博弈

BioNTech’s Legal Crossfire and Vaccine Pipeline Converge on a Pivotal Earnings Moment

kashif hafeez -

BioNTech双线布局：BMS加码商业化押注，XFG疫苗获批能否撑起Q4盈亏平衡？

BioNTech财报前夕突获欧盟放行：XFG疫苗获批上市，肿瘤转型与专利诉讼交织成多空博弈焦点

Brett Shapiro -

BioNTech的“双重叙事”：8月4日财报前的肿瘤数据赌局与10亿美元回购信号

BioNTech腹背受敌：8月4日财报前专利诉讼与肿瘤管线上演“冰火两重天”

BioNTech’s $16.8 Billion Question: Can Oncology Data Justify the Wait?

BioNTech转型关键期：专利诉讼阴云与肿瘤管线曙光交织，8月4日二季报成多空分水岭

Brett Shapiro -

BioNTech四面楚歌：专利诉讼与肿瘤转型的双重博弈，8月财报成关键变量

kashif hafeez -

BioNTech肿瘤转型遭遇“技术性僵局”：ARK清仓与百日均线拉锯下的8月4日关键节点

Brett Shapiro -

BioNTech Faces a Legal Storm as Q1 Revenue Misses and a $1 Billion Buyback Awaits Judgment Day

BioNTech腹背受敌：8月4日二季报能否化解专利围城与转型困局？

BioNTech二季报倒计时：肿瘤转型成效将迎市场“大考”

kashif hafeez -

BioNTech’s HIV Vaccine Moves to Clinic Amid Patent Fights and a Shrinking COVID Business

BioNTech专利诉讼四面来袭，肿瘤管线六项数据成破局关键

kashif hafeez -
123...12Page 1 of 12